Antiphospholipid antibodies in young adults with stroke

Robin L. Brey

Research output: Contribution to journalReview articlepeer-review

55 Scopus citations


Background. Antiphospholipid antibodies have been associated with a clinical syndrome consisting thrombosis and recurrent, unexplained fetal loss. Methods. The literature pertaining to stroke associated with antiphospholipid antibodies, with emphasis on stroke in young adults, was reviewed. Results. Antiphospholipid antibodies are an independent risk factor for stroke in young adults in five of six studies. Multiple antiphospholipid specificities or the Lupus Anticoagulant were tested in addition to anticardiolipin antibody in these studies. In the single study that found no increased risk for stroke, only anticardiolipin fsantibody was tested. Only one of these studies evaluated for risk of recurrent stroke in young adults with antiphospholipid antibodies and found it to be increased. No treatment trials have been conducted in young adults with antiphospholipid antibodies and stroke. In the single treatment trial comparing aspirin and low-INR producing doses of warfarin to prevent recurrent stroke, both were found to be equally effective. Conclusions. Antiphospholipid antibodies, particularly Lupus Anticoagulant, is an independent risk factor for first and possibly recurrent ischemic stroke in young adults. The best therapeutic strategy for preventing antiphospholipid antibody-associated recurrent stroke is not clear.

Original languageEnglish (US)
Pages (from-to)105-112
Number of pages8
JournalJournal of Thrombosis and Thrombolysis
Issue number2
StatePublished - Oct 2005


  • Anticardiolipin antibody
  • Antiphospholipid antibodies
  • Antiphospholipid syndrome
  • Cerebral ischemia
  • Lupus anticoagulant

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Antiphospholipid antibodies in young adults with stroke'. Together they form a unique fingerprint.

Cite this